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Intra-abdominal Complications of Sarcoidosis
Kristin Loening MacArthur,1 Faripour Forouhar,2 George Yung-Hsing Wu1
Sarcoidosis is an inflammatory disease characterized by non-caseating granulomas in the absence of other
autoimmune processes, infectious diseases, or foreign agents. The etiology of sarcoidosis is not completely
understood. Several organ systems can be affected, of which the most frequently involved include the
lungs and lymph nodes. Intra-abdominal sarcoidosis is less common, but can be found in the absence of
pulmonary or lymphatic disease. Intra-abdominal sarcoidosis is most often asymptomatic. However,
long-standing unrecognized disease can result in life-threatening complications. The identification, mon-
itoring and prevention of these complications will be discussed, with emphasis on both clinical and his-
tological presentations of intra-abdominal sarcoidosis.
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Introduction
Sarcoidosis is a systemic inflammatory disease
marked by diversity of clinical presentation, organ
involvement and disease progression. Sarcoidosis
affects individuals worldwide, occurring most
commonly in young middle-aged adults. Epi-
demiological reports of sarcoidosis vary among
racial groups, but the worldwide prevalence varies
between 2–60 per 100,000 people, with higher
rates seen in patients of Irish and Scandinavian
descent.1 Sarcoidosis in Chinese patients in Taiwan
has been reported to be relatively rare, although
incidence has increased from 0.4/100,000 in the
1980s to 2.7/100,000 in the 1990s.2 In the United
States, African Americans have a three-fold higher
age-adjusted incidence of 35.5/100,000 versus
Caucasian Americans at 10.9/100,000.3 The dis-
ease affects women more frequently than men
and is usually diagnosed in young adults between
20–40 years of age.4 A second incidence peak after
age fifty has been found in females in Japan and
Scandinavia.5 Compared to patients in Western
countries, Chinese patients in Taiwan have been
reported to present later in life, more commonly
have intrathoracic involvement, and less fre-
quently have hypercalcemia and hyperglobuline-
mia.6 In a report from Singapore, the calculated
annual incidence of sarcoidosis was 0.23/100,000
for Chinese, 4.57/100,000 for Indians and
1.30/100,000 for Malays. The overall annual inci-
dence of sarcoidosis was 0.56/100,000.7 Overall,
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the mortality of sarcoidosis has been reported to
be 1–5%, and is usually attributed to progressive
respiratory insufficiency, central nervous system
involvement, or myocardial compromise.5,8
This multisystem disorder usually involves the
lungs (> 90%) and the lymphoid system (30%)
(Figure 1), and classically presents as intratho-
racic hilar lymphadenopathy. Other sites include
the heart (5%), skin (25%), and eyes (11–83%),
and less commonly the nervous system, muscles,
bones, and salivary glands.5 The hepatobiliary and
gastrointestinal tracts can also be affected even in
patients without intrathoracic disease. Liver in-
volvement follows lung and lymph nodes in fre-
quency, although it is usually asymptomatic, and
does not often cause significant organ dysfunction.
Approximately 50–80% of autopsy and biopsy
specimens of patients with systemic sarcoidosis
have been shown to have detectable hepatic sar-
coidosis.9 In contrast, sarcoidosis of the gut is ex-
tremely rare with clinical symptoms present in
< 1% of patients.10,11 Autopsy reports are variable,
with gut involvement anywhere from 0% to 10%
of patients with proven systemic sarcoidosis.9,12,13
Gut involvement is usually associated with con-
comitant pulmonary disease, and is most com-
monly asymptomatic. Clinical complications of
hepatobiliary and gut sarcoidosis are rare, but
are important to recognize as they may cause sig-
nificant morbidity and mortality.
The sine qua non for the diagnosis of sarcoido-
sis is the histological demonstration of epithe-
lioid granulomatous reactions in the absence of
other granulomatous diseases such as tuberculo-
sis, fungal infections, inflammatory bowel dis-
ease, malignancy, and delayed-type hypersensitivity
to foreign antigens.14 The granulomata are typi-
cally non-necrotizing (Figure 1). However, central
fibrinoid necrosis may occur (Figure 2) and rarely,
it can be significant. Caseation necrosis never 
occurs. Typically, there is a sparse population of
lymphocytes in the mantle zone around the
granulomata (Figures 3 and 4). This is in contrast
to the granulomatous reaction formed in response
to infectious diseases. Biopsies showing histologi-
cal features in two or more organs is most specific
for sarcoidosis, but clinical and radiographic fea-
tures can aid in making the diagnosis.
The etiology of sarcoidosis is still not com-
pletely understood although it has been suggested
that the disease arises in genetically susceptible
individuals who are exposed to deleterious envi-
ronmental agents. Certain familial clusters and
common human leukocyte antigens have sug-
gested a polyclonal inheritance pattern, with his-
tocompatibility leukocyte antigens (HLA-A1, B8,
DRB1, DQB1, DRB3) correlating with suscepti-
bility in different populations.15 No particular in-
citing environmental agent has been proven, but
several examples have been proposed. These in-
clude viruses such as herpesviruses, retroviruses,
Figure 1. Lymph node showing tight non-necrotizing 
epithelioid granulomata, typical of sarcoidosis. (Hematoxylin
and eosin; original magnification, 100×).
Figure 2. Liver biopsy with necrotizing sarcoidal granuloma.
Fibrinoid necrosis in the center of necrotizing type sarcoidal
granulomata (asterisk). This is quite different from caseation
necrosis of tuberculosis and suppurative necrosis in Yersinia.
Multinucleated giant cell (arrow). (Hematoxylin and eosin;
original magnification, 100×).
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and cytomegalovirus, as well as bacteria including
Borrelia burgdorferi, mycobacteria and mycoplasma.
The immunologic abnormalities demonstrated in
sarcoidosis usually encompass an antigen-triggered
abnormal Th-1 response accompanied by cytokine
production. This inflammatory pattern results in
local macrophage recruitment, granuloma forma-
tion, injury and eventual fibrosis.1
The following will outline both clinical man-
ifestations, and complications of intra-abdominal
sarcoidosis.
Sarcoidosis of the Liver
Although more than half of patients with sar-
coidosis have hepatic involvement on biopsy,
only 10–30% have laboratory evidence of liver
disease.1,16 The clinical presentation of hepatic
sarcoidosis is usually asymptomatic, and despite
the presence of granulomas on biopsy or on ra-
diologic studies, there is rarely organ dysfunction.
However, there are some clinical signs that may
suggest hepatic sarcoidosis, and may suggest need
for a liver biopsy. Fever and arthralgias, although
not specific, are present in the majority of indi-
viduals with active hepatic sarcoidosis.17,18 More
specific symptoms include jaundice, pruritis, right
upper quadrant abdominal pain and hepato-
megaly.10,19 These symptoms most likely result
from chronic cholestasis due to intrahepatic gran-
ulomas in the portal space (Figure 4B) or through
external compression of bile ducts from granulo-
mas in extrahepatic lymph nodes. Chronic in-
flammation and fibrosis can result in long-term
complications including portal hypertension,20
A B
Figure 3. (A and B) Liver biopsy showing a conglomerate of sarcoidal granulomata. Note prominence of fibrosis and
scarcity of lymphocytic infiltration (portal location). Note also the advantage of reticulin stain in exhibiting the architec-
ture of granulomatous reaction. Portal area showing granulomatous reaction and extreme fibrosis (asterisk). Reticulin
outlining granulomatous complex (arrow). (Hematoxylin and eosin; original magnification, 40×).
A B
Figure 4. Sarcoidosis involving a portal area of the liver. (A) Sarcoid granuloma (arrow; hematoxylin and eosin; original
magnification, 400×). (B) The granulomatous complex (asterisk) surrounded by extent of fibrosis (blue) and bile duct in-
jury by trichrome stain (arrow). (Trichrome, original magnification, 400×).
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Budd-Chiari syndrome,21 and cirrhosis,19,22,23
although the prevalence of these complications
is estimated to be less than 1%.18 There may be an
additional correlation between chronic hepatic
sarcoidosis and hepatocellular carcinoma.24,25
Clinical suspicion of sarcoid involvement of
the liver may be derived from elevated laboratory
findings. Elevations in alkaline phosphatase
and/or gamma-glutamyl-transpeptidase have been
shown to correlate highly with cholestasis and
liver involvement.10,26 Alanine aminotransferase
and aspartate aminotransferase can be mildly el-
evated in approximately 50% of asymptomatic
patients with hepatic sarcoidosis.26 Hyperglobu-
linemia is also common. Elevated angiotensin-
converting enzyme levels (ACE) occur in up to
60% of patients with active sarcoidosis, but less
so in chronic sarcoidosis, and patients on cortico-
steroids. Normal ACE levels do not rule out dis-
ease, but elevated ACE levels can be helpful in
discerning sarcoidosis from other granulomatous
diseases.27,28
Radiological studies including computed to-
mography (CT) or magnetic resonance imaging
(MRI) may reveal hepatomegaly and granulomas
represented by multiple hypointense or hypoat-
tenuating nodules. Multiple hepatic nodules may
be confused with other diseases, including metas-
tasis or other granulomatous diseases, but con-
comitant splenic granulomas may narrow the
suspicion to either sarcoidosis or lymphoma.29
Ultimately, liver biopsy is the definitive method
of diagnosis of hepatic sarcoidosis. Hepatic sarcoid
granulomata are most frequently found within
the portal tracts, and in the periportal zone. The
granulomata are often bare with sparse surround-
ing lymphocytic infiltration (Figures 2 and 4).
This is in contrast to primary biliary cirrhosis and
infectious disorders, which have a more pro-
nounced inflammatory reaction. It is prudent to
perform stains for acid-fast mycobacteria and fungi
to further differentiate sarcoidosis from infectious
granulomatous diseases. Typically, the granulo-
mata in hepatic sarcoidosis are non-necrotizing.
However, some may be significantly fibrotic with 
or without fibrinoid necrosis (Figures 2 and 4).
Mild nonspecific lobular hepatitis often accom-
panies the granulomatous reaction in the portal
areas, and rarely may be prominent in symptomatic
patients. The damaged bile ducts in sarcoidosis may
also mimic primary biliary cirrhosis (Figures 4A
and 4B). These two entities may coexist. However,
the morphology, the presence of extrahepatic dis-
ease, and the status of anti-mitochondrial anti-
body are useful in differentiating between the
two entities. Over time, persistent granulomata
may result in significant collagen accumulation
(Figures 3 and 4). The conglomerate of granulo-
mata can result in chronic intrahepatic cholestasis,
decreased numbers of interlobular bile ducts, and
periductal fibrosis.22 Ultimately, progression of
disease can result in micronodular biliary cirrhosis,
portal hypertension and ascites.
The role of treatment for hepatic sarcoidosis is
largely dependent on clinical presentation. If
symptoms such as fever, fatigue, weight loss or
abdominal pain persist, then treatment with cor-
ticosteroids may be instituted. Steroids have been
shown to reduce liver size and the number of gran-
ulomas.10 Prednisone at low doses (10–20 mg) is
usually sufficient for mild constitutional symp-
toms, but higher doses (40–60 mg) may be needed
for severe symptoms such as jaundice and pruri-
tis.30 The duration of therapy should be determined
by clinical and laboratory response, and relapsing
symptoms may require long-term therapy.
In asymptomatic patients with elevated liver
enzymes, it is unclear whether corticosteroids have
a role in preventing liver damage. Studies have
shown that treatment with corticosteroids can re-
solve or improve elevated aminotransferase lev-
els,26,31 although many untreated patients will
have spontaneous normalization of liver enzymes
when followed over a course of 5 years.26 However,
lack of long-term follow-up of these patients pre-
cludes definite conclusions regarding the effects
of corticosteroid treatment on disease progression.
It has been shown that once disease progresses to
portal hypertension, chronic cholestasis, or fibro-
sis, corticosteroids may no longer have a benefi-
cial effect.10,20 The decision to treat asymptomatic
individuals should, therefore, take place in cases
K.L. MacArthur, et al
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of persistently elevated liver enzymes where the
benefits of corticosteroids outweigh the risks of
side effects. More studies are needed to address
this issue.
Other medications for therapy that are currently
under exploration include methotrexate, aza-
thioprine and infliximab.30,31–33 Ursodeoxycholic
acid has been used to manage symptoms of
chronic cholestasis.34 Liver transplantation is re-
served for refractory, end stage cirrhosis or portal
hypertension, although sarcoidosis may redevelop
in the new organ after transplantation.32
Sarcoidosis of the Gut
Upper gut involvement
Upper gastrointestinal areas including the orophar-
ynx (Figure 5) and salivary glands (Figure 6) are
potential sites of sarcoid involvement. Sarcoidosis
has also been reported in the esophagus, albeit
rarely. The most frequent symptomatic presenta-
tion of esophageal involvement is dysphagia. This
symptom can be due to motility disorders, space
occupying granulomatous lesions, pseudodiver-
ticulae, or strictures.35,36 Motility disorders can
be caused by localized mucosal granulomas
compromising intrinsic esophageal contractions,
external compression by affected paraesophageal
lymph nodes, or by granulomatous nerve involve-
ment.13 Sarcoidosis has been shown to cause sec-
ondary achalasia due to infiltration of the distal
esophagus or direct involvement of the enteric
nervous system and Auerbach’s plexus.37 This
clinical complication may benefit from myotomy.
Among all of the gut sites, sarcoidosis is most
commonly found in the stomach. Approximately
10% of systemic sarcoidosis patients were found
on autopsy to have gastric involvement, most often
in the antrum.38 The majority of these cases were
asymptomatic. When present, reported symp-
toms included postprandial epigastric pain, early
satiety, weight loss, nausea, outlet obstruction, or
acute bleeding from ulcers.11,35,39 There are two
main patterns of gastric sarcoidosis, differenti-
ated by local versus diffuse mucosal involvement.
Localized granulomatous infiltration of the mu-
cosa may lead to endoscopic findings of ulcera-
tions (mainly in the antrum, pylorus and lesser
curvature), gastritis, hyperemia with friable mu-
cosa, or nodular irregularities resembling polyps.
In contrast, diffuse granulomatous infiltration
typically results in fibrosis, which leads to wide-
spread mucosal thickening, rigidity, and reduced
lumen size.13,37,38 It may resemble linitis plastica
in appearance, and should be differentiated from
gastric carcinoma. An unequivocal diagnosis of
gastric sarcoidosis can only be made by biopsy.
Workup must exclude other causes of granu-
lomatous gastritis including infection, foreign
body giant cell reaction (especially in intravenous
drug use), reaction to food, and malignancy. 
Figure 5. Saracoidosis of the oropharynx. Granulomata are
present deep in the submucosa. Surface squamous epithe-
lium (arrow) and sarcoid granulomata (asterisk). (Hematoxylin
and eosin; original magnification, 40×).
Figure 6. Parotid gland showing involvement with sarcoido-
sis and granulomatous response (arrow) (hematoxylin and
eosin; original magnification, 400×).
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The diagnosis should be confirmed by additional
organ involvement.
Small bowel involvement is the least com-
mon site of all in gut sarcoidosis.13 Symptoms
include abdominal pain, diarrhea, weight loss,
malabsorption, obstruction or hemorrhage due to
ulcerations.35,40,41 Malabsorption has presented
in patients as a protein-losing enteropathy or
megaloblastic anemia secondary to B12 or folate
deficiency.42,43 B12 deficiency can be attributed to
either terminal ileum disease or achlorhydria sec-
ondary to gastric involvement. Intestinal obstructive
symptoms and lymphangiectasia are usually the
result of extrinsic compression by abdominal and
mesenteric lymph nodes. These findings may also
occur when the lumen size is reduced secondary to
mucosal granulomatous lesions, as shown in one
patient presenting with a duodenal obstruction.44
Diagnosis of small bowel sarcoidosis can be
difficult, especially in differentiating between
diseases with similar presentations, including
Crohn’s disease, Whipple’s disease, celiac disease,
carcinoma, foreign body reactions and intestinal
tuberculosis. The differentiation between sarcoido-
sis and Crohn’s disease is particularly difficult, but
indicators that may favor the diagnosis of sar-
coidosis include elevated ACE levels, superficial
mucosal involvement versus transmural inflam-
mation, and absence of perianal disease, fistulas,
and strictures.44 Both Crohn’s disease and sar-
coidosis can exhibit cutaneous manifestations
such as erythema nodosum. However, Crohn’s dis-
ease rarely affects the respiratory system.43 Despite
these differences, it has been postulated that sar-
coidosis and Crohn’s disease lie on a similar
continuum of disease pathophysiology, and can
overlap in presentation and response to treatment.
Lower gut involvement
Lower gut involvement in sarcoidosis includes
the appendix, colon, and rectum. The sigmoid
colon is the site of most frequent involvement.13
Colorectal sarcoidosis can occur in the presence of
grossly normal appearing mucosa. Symptoms of
colorectal involvement include diarrhea, abdom-
inal pain, tenesmus, or hematochezia. Obstruction
causing pain, distention, constipation, and vom-
iting has also been described.45 Colonic sarcoid
granulomatous lesions may resemble polyps and
submucosal tumors. Others may form aphthous
erosions or ulcers.46,47 If the lesions are necrotizing,
it is important to distinguish sarcoid from Yesinia
colitis. Yersinia granulomata typically show a more
coagulative-type necrosis with much nuclear de-
bris, and are often stellate and elongated in shape.
They typically occur in the region of cecum and
appendix. Cultures and serology can be helpful in
making the diagnosis. Complications of colonic
sarcoidosis include mucosal edema, submucosal
hemorrhage and anemia.45,48 Manifestations of
appendiceal sarcoidosis include appendicitis, ap-
pendiceal perforation and abscess formation.49
Benign asymptomatic gut sarcoidosis likely
does not warrant treatment. However, sympto-
matic involvement can be treated with systemic
corticosteroids. Two-thirds of patients tend to
have a dramatic resolution of symptoms with
steroid treatment. Prednisone 20–40 mg daily is
usually effective as a starting dose, and can be ta-
pered with clinical improvement over a period of
3–12 months depending on clinical response.5,13
Antacids and metoclopramide can be used for
symptomatic relief of abdominal pain or delayed
gastric emptying.40 Biologic agents such as metho-
trexate, chlorambucil, azathioprine, infliximab,
and cyclosporin may have an alternative role in
treating gastrointestinal sarcoidosis.13 Surgical 
intervention may be required for refractory or
emergent disease complications including massive
hemorrhage, perforation, obstruction, strictures
or abscess formation.
Sarcoidosis of Other Intra-abdominal
Sites
Peritoneum
Sarcoidosis can rarely affect the peritoneum.50–52
The most frequent clinical presentation is exuda-
tive ascites (both bloody and non-bloody) and
abdominal pain resulting from multiple granulo-
matous nodules studding the peritoneum. Patients
K.L. MacArthur, et al
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may also present with a single peritoneal lesion.
For example, one patient presented with a solitary
mass at the site of an old appendectomy scar.53
Due to close gross visual resemblance, peritoneal
sarcoidosis should be differentiated between carci-
nomatosis and tuberculous peritonitis. Peritoneal
symptomatology usually resolves within a few
weeks either spontaneously or after a short course
of corticosteroids.53,54
Pancreas
Pancreatic sarcoidosis has been discovered on
autopsy in 1–3% of cases of systemic sarcoidosis,
but rarely presents symptomatically during life.55
Typical symptoms of pancreatic involvement in-
clude abdominal pain, weight loss, obstructive
jaundice, nausea and vomiting.17 Elevated amylase
and lipase are possible.56 Direct tissue infiltra-
tion, duct obstruction, or constrictive peripancre-
atic lymphadenopathy may contribute to these
symptoms.57 Pancreatic involvement can be dif-
fusely nodular, or manifest as a pancreatic mass,
most often found in the head of the pancreas.58
This finding can mimic pancreatic cancer and
pancreaticoduodenectomy may be required es-
pecially in cases of duct obstruction or neoplastic
exclusion.57 Radiological imaging studies of pan-
creatic sarcoidosis include CT findings of dilata-
tion of the common bile duct and pancreatic duct,
solitary ill-defined pancreatic masses, or enlarged
lymph nodes. MRI can show multiple masses
with low signal intensity on T1, mild high signal
intensity on T2, and decreased enhancement after
gadolinium administration compared to the nor-
mal pancreas.59 Endoscopic ultrasound may also
be used to detect pancreatic inflammation in the
setting of suspected pancreatic sarcoidosis.56
Studies on the efficacy of medical therapy for
pancreatic sarcoidosis have been inconclusive;
some patients were found to benefit from corti-
costeroids, while others resolved spontaneously,
and a few required surgical intervention.17
Gallbladder
Sarcoidosis of the biliary system has been 
reported.60 In one patient without hepatic 
involvement, sarcoidosis was found in the cystic
duct and the gallbladder neck. The noncaseating
granulomas led to stenosis of the cystic duct 
and the hepatic bile duct, resulting in a presenta-
tion of obstructive jaundice. The patient’s symp-
toms resolved after cholecystectomy and left
hepatojejunostomy.61
Spleen
Sarcoidosis of the spleen is found most often in
the presence of systemic disease rather than as an
isolated entity.62 Splenic sarcoidosis is usually
asymptomatic, but can cause splenomegaly, ab-
dominal pain, and hematologic abnormalities
such as leukopenia.63 Splenic infiltration can be
homogeneous or isolated as multiple granulo-
matous nodules.64,65 Splenic lesions are readily
seen on CT or MRI as low-attenuating lesions, and
can easily be confused with lymphoma, metastases
or infections.29 In the setting of defined multi-
organ sarcoidosis and asymptomatic splenic le-
sions, intervention is not required. Corticosteroids
are successful in reducing splenomegaly and no-
dularity in some patients.66 Splenectomy (either
open or laparoscopic) can be performed for symp-
tomatic relief, prophylaxis for splenic rupture,
and exclusion of malignancy. Splenectomy does
not alter the course or progression of systemic
sarcoidosis.62
Conclusions
Sarcoidosis is a systemic inflammatory disease of
uncertain etiology, most commonly associated
with pulmonary and lymphatic manifestations.
Hepatic sarcoidosis is relatively common, although
most often asymptomatic. Gut, splenic, pancreatic,
biliary, and peritoneal sarcoidosis occur rarely,
and are usually asymptomatic. The consequences
of hepatic and gastrointestinal sarcoidosis when
present can lead to significant morbidity and
mortality. Physicians and patients should be
aware, and monitor progression of symptoms,
pertinent laboratory findings, and initiate treat-
ment when appropriate.
Gastrointestinal sarcoidosis
J Formos Med Assoc | 2010 • Vol 109 • No 7 491
References
1. Baughman RP, Lower EE. Sarcoidosis. In Fauci A,
Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL,
Loscalzo J, editors. Harrison’s principles of internal medi-
cine. 17th edition. New York: McGraw Hill, 2008.
2. Perng RP, Chou KT, Chu H, et al. Familial sarcoidosis in
Taiwan. J Formos Med Assoc 2007;106:499–503.
3. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences
in sarcoidosis incidence: a 5-year study in a health mainte-
nance organization. Am J Epidemiol 1997;145:234–41.
4. Iwai K, Tachibana T, Takemura T, et al. Pathological stud-
ies on sarcoidosis autopsy. I. Epidemiological features of
320 cases in Japan. Acta Pathol Jpn 1993;43:372–6.
5. Costabel U, Hunninghake GW. ATS/ERS/WASOG state-
ment on sarcoidosis. Sarcoidosis Statement Committee.
American Thoracic Society. European Respiratory Society.
World Association for Sarcoidosis and Other Granulomatous
Disorders. Eur Respir J 1999;14:735–7.
6. Perng RP, Chen JH, Tsai TT, et al. Sarcoidosis among
Chinese in Taiwan. J Formos Med Assoc 1997;96:697–9.
7. Anantham D, Ong SJ, Chuah KL, et al. Sarcoidosis in
Singapore: epidemiology, clinical presentation and ethnic
differences. Respirology 2007;12:355–60.
8. Iwai K, Tachibana T, Hosoda Y, et al. Sarcoidosis autopsies in
Japan. Frequency and trend in the last 28 years. Sarcoidosis
1988;5:60–5.
9. Ebert EC, Kierson M, Hagspiel KD. Gastrointestinal and
hepatic manifestations of sarcoidosis. Am J Gastroenterol
2008;103:3184–92, quiz 3193.
10. Israel HL, Sones M. Sarcoidosis; clinical observation on
one hundred sixty cases. AMA Arch Intern Med 1958.
11. Akinyemi E, Rohewal U, Tangorra M, et al. Gastric sar-
coidosis. J Natl Med Assoc 2006;98:948–9.
12. Longcope WT, Freiman DG. A study of sarcoidosis; based
on a combined investigation of 160 cases including 30 au-
topsies from The Johns Hopkins Hospital and Massachusetts
General Hospital. Medicine (Baltimore) 1952;31:1–132.
13. Vahid B, Spodik M, Braun KN, et al. Sarcoidosis of gastroin-
testinal tract: a rare disease. Dig Dis Sci 2007;52:3316–20.
14. Chesnutt, MS, Gifford AH, Prendergast TJ. Pulmonary dis-
orders. In McPhee SJ, Papadakis MA, Tierney LM, eds.
Current medical diagnosis & treatment 2010, 49th edition.
New York: McGraw-Hill, 2010.
15. Lazarus A. Sarcoidosis: epidemiology, etiology, pathogen-
esis, and genetics. Dis Mon 2009;55:649–60.
16. Chen ES, D Moller DR. Sarcoidosis. In Imboden JB, Hellman
DB, Stone JH, eds. Current Rheumatology Diagnosis and
Treatment, 2nd edition. New York: McGraw Hill, 2004.
17. Harder H, Büchler MW, Fröhlich B, et al. Extrapulmonary
sarcoidosis of liver and pancreas: a case report and review
of literature. World J Gastroenterol 2007;13:2504–9.
18. Israel HL, Margolis ML, Rose LJ. Hepatic granulomatosis
and sarcoidosis. Further observations. Dig Dis Sci 1984;
29:353–6.
19. Blich M, Edoute Y. Clinical manifestations of sarcoid liver
disease. J Gastroenterol Hepatol 2004;19:732–7.
20. Valla D, Pessegueiro-Miranda H, Degott C, et al. Hepatic
sarcoidosis with portal hypertension. A report of seven
cases with a review of the literature. Q J Med 1987;63:
531–44.
21. Deniz K, Ward SC, Rosen A, et al. Budd-Chiari syndrome
in sarcoidosis involving liver. Liver Int 2008;28:580–1.
22. Malhotra A, Naniwadekar A, Sood G. Hepatobiliary and
pancreatic: cirrhosis secondary to hepatic sarcoidosis. 
J Gastroenterol Hepatol 2008;23:1942.
23. Gupta S, Faughnan ME, Prud’homme GJ, et al. Sarcoidosis
complicated by cirrhosis and hepatopulmonary syn-
drome. Can Respir J 2008;15:124–6.
24. Chalasani P, Vohra M, Sheagren JN. An association of sar-
coidosis with hepatocellular carcinoma. Ann Oncol 2005;
16:1714–5.
25. Wong VS, Adab N, Youngs GR, et al. Hepatic sarcoidosis
complicated by hepatocellular carcinoma. Eur J Gastroenterol
Hepatol 1999;11:353–5.
26. Vatti R, Sharma OP. Course of asymptomatic liver involve-
ment in sarcoidosis: role of therapy in selected cases.
Sarcoidosis Vasc Diffuse Lung Dis 1997;14:73–6.
27. Silverstein E, Friedland J, Kitt M, et al. Increased serum
angiotensin converting enzyme activity in sarcoidosis. Isr J
Med Sci 1977;13:995–1000.
28. Lieberman J. Elevation of serum angiotensin-converting-
enzyme (ACE) level in sarcoidosis. Am J Med 1975;59:
365–72.
29. Koyama T, Ueda H, Togashi K, Umeoka S, Kataoka M,
Nagai S. Radiologic manifestations of sarcoidosis in vari-
ous organs. Radiographics 2004;24:87–104.
30. Rose AS, Tielker MA, Knox KS. Hepatic, ocular, and cuta-
neous sarcoidosis. Clin Chest Med 2008;29:509–24, ix.
31. Kennedy PT, Zakaria N, Modawi SB, et al. Natural history
of hepatic sarcoidosis and its response to treatment. Eur J
Gastroenterol Hepatol 2006;18:721–6.
32. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis
with infliximab. Chest 2005;127:1064–71.
33. Baughman RP. Methotrexate for sarcoidosis. Sarcoidosis
Vasc Diffuse Lung Dis 1998;15:147–9.
34. Bécheur H, Dall’osto H, Chatellier G, et al. Effect of ur-
sodeoxycholic acid on chronic intrahepatic cholestasis due
to sarcoidosis. Dig Dis Sci 1997;42:789–91.
35. Wasfi YS, Margolis ML. A 45-year-old man with severe dys-
phagia and pulmonary infiltrates. Chest 2007;131:1256–9.
36. Ohshimo S, Theegarten D, Tötsch M, Moege et al.
Esophageal sarcoidosis presenting as pseudodiverticulum.
Sarcoidosis Vasc Diffuse Lung Dis 2008;25:64–7.
37. Lukens FJ, Machicao VI, Woodward TA, et al. Esophageal
sarcoidosis: an unusual diagnosis. J Clin Gastroenterol
2002;34:54–6.
38. Friedman M, Ali MA, Borum ML. Gastric sarcoidosis: a case
report and review of the literature. South Med J 2007;100:
301–3.
K.L. MacArthur, et al
492 J Formos Med Assoc | 2010 • Vol 109 • No 7
39. Fireman Z, Sternberg A, Yarchovsky Y, et al. Multiple antral
ulcers in gastric sarcoid. J Clin Gastroenterol 1997;24:97–9.
40. Briley CA Jr, Jackson DC, Johnsrude IS, et al. Acute gas-
trointestinal hemorrhage of small-bowel origin. Radiology
1980;136:317–9.
41. Sprague R, Harper P, McClain S, et al. Disseminated gas-
trointestinal sarcoidosis. Case report and review of the lit-
erature. Gastroenterology 1984;87:421–5.
42. Godeau B, Farcet JP, Delchier JC, et al. Protein-losing 
enteropathy in gastrointestinal sarcoidosis associated with
malignant lymphoma. J Clin Gastroenterol 1992;14:78–80.
43. MacRury SM, McQuaker G, Morton R, et al. Sarcoidosis:
association with small bowel disease and folate deficiency.
J Clin Pathol 199;45:823–5.
44. Noël JM, Katona IM, Piñeiro-Carrero VM. Sarcoidosis re-
sulting in duodenal obstruction in an adolescent. J Pediatr
Gastroenterol Nutr 1997;24:594–8.
45. Beniwal RS, Cummings OW, Cho WK. Symptomatic 
gastrointestinal sarcoidosis: case report and review of the 
literature. Dig Dis Sci 2003;48:174–8.
46. Veitch AM, Badger I. Sarcoidosis presenting as colonic
polyposis: report of a case. Dis Colon Rectum 2004;47:
937–9.
47. Ushiki A, Koizumi T, Kubo K, et al. Colonic sarcoidosis
presenting multiple submucosal tumor-like lesions. Intern
Med 2009;48:1813–6.
48. Akdoğan M, Ulas¸ M, Kayhan B, et al. Gastrointestinal sar-
coidosis mimicking colonic cancer. Turk J Gastroenterol
2008;19:136–8.
49. Munt PW. Sarcoidosis of the appendix presenting as ap-
pendiceal perforation and abscess. Chest 1974;66:295–7.
50. Bernaciak J, Spina JC, Curros ML, et al. Case report: peri-
toneal sarcoidosis in an unusual location. Semin Respir
Crit Care Med 2002;23:597–600.
51. Uthman IW, Bizri AR, Khalifeh MJ. Peritoneal sarcoidosis.
Semin Arthritis Rheum 2002;31:353.
52. Robertson LE Jr, Cunningham JT. Primary peritoneal sar-
coidosis. Dig Dis Sci 1990;35:1545–8.
53. Uthman IW, Bizri AR, Shabb NS, et al. Peritoneal sar-
coidosis: case report and review of the literature. Semin
Arthritis Rheum 1999;28:351–4.
54. Bourdillon L, Lanier-Gachon E, Stankovic K, et al. Lofgren
syndrome and peritoneal involvement by sarcoidosis: case
report. Chest 2007;132:310–2.
55. Shukla M, Hassan MF, Toor V, et al. Symptomatic pancre-
atic sarcoidosis. Case report and review of literature. JOP
2007;8:770–4.
56. Romboli E, Campana D, Piscitelli L, et al. Pancreatic involve-
ment in systemic sarcoidosis. A case report. Dig Liver Dis
2004;36:222–7.
57. Caceres M, Sabbaghian MS, Braud R, et al. Pancreatic sar-
coidosis: unusual presentation resembling a periampullary
malignancy. Curr Surg 2006;63:179–85.
58. Curran JF Jr, Curran JF Sr. Boeck’s sarcoid of the pancreas.
Surgery 1950;28:574–8.
59. Baroni RH, Pedrosa I, Tavernaraki E, et al. Pancreatic sar-
coidosis: MRI features. J Magn Reson Imaging 2004;
20:889–93.
60. Lloyd-Davies RW, Forbes GB. Sarcoidosis of the gall bladder.
Gastroenterology 1965;49:287–90.
61. Kusielewicz D, Duchatelle V, Valeyre D, et al. Obstructive
jaundice caused by granulomatous stenosis of the extra-
hepatic bile ducts in sarcoidosis. Gastroenterol Clin Biol
1988;12:664–7. [In French]
62. Zia H, Zemon H, Brody F. Laparoscopic splenectomy for
isolated sarcoidosis of the spleen. J Laparoendosc Adv
Surg Tech A 2005;15:160–2.
63. Rodríguez-García JL, Picazo J, Mira C, et al. Systemic sarcoi-
dosis with spleen involvement. Postgrad Med J 2001;77:265.
64. Penna C, Deroide GA. Images in clinical medicine. Splenic
sarcoidosis. N Engl J Med 2003;349:e16.
65. Warshauer DM. Splenic sarcoidosis. Semin Ultrasound CT
MR 2007;28:21–7.
66. A Mohan, Sood R, Shariff N, et al. Sarcoidosis manifesting
as massive splenomegaly: a rare occurrence. Am J Med Sci
2004;328:170–2.
